Status:
UNKNOWN
Angiogenesis Inhibitor Plus Anti-PD-1/PD-L1 Antibody in Advanced Esophageal Cancer
Lead Sponsor:
The First Affiliated Hospital of Zhengzhou University
Conditions:
Esophageal Neoplasms
Eligibility:
All Genders
Brief Summary
The combination of an anti-PD-1/PD-L1 antibody with an angiogenesis inhibitor has shown efficacy in many cancers.The purpose of this study is to confirm that the combination of these two drugs can ben...
Eligibility Criteria
Inclusion
- Esophageal cancer confirmed by histopathology or cytology
- Unresectable locally advanced/recurrent or metastatic esophageal cancer, or progression after neoadjuvant or adjuvant therapy
- Esophageal cancer patients who benefit from the use of an anti-PD-1/PD-L1 antibody with an angiogenesis inhibitor evaluated by the researchers
- Patients who sign informed consent and voluntarily join the study
Exclusion
- Patients who are recommended not using an anti-PD-1/PD-L1 antibody or an angiogenesis inhibitor in the instructions, or other patients who are judged by the investigators to be unsuitable in the study
- Patients who are undergoing treatment regimen of blind trial
Key Trial Info
Start Date :
May 5 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
May 5 2025
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT05349045
Start Date
May 5 2022
End Date
May 5 2025
Last Update
April 27 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China, 450000